| Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study M Arnold, MJ Rutherford, A Bardot, J Ferlay, TML Andersson, ... The Lancet Oncology 20 (11), 1493-1505, 2019 | 875 | 2019 |
| The impact of comorbidity on cancer and its treatment D Sarfati, B Koczwara, C Jackson CA: a cancer journal for clinicians 66 (4), 337-350, 2016 | 681 | 2016 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 370 | 2017 |
| Changes in colorectal cancer incidence in seven high-income countries: a population-based study M Araghi, I Soerjomataram, A Bardot, J Ferlay, CJ Cabasag, DS Morrison, ... The lancet Gastroenterology & hepatology 4 (7), 511-518, 2019 | 364 | 2019 |
| The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI G Kong, C Jackson, DM Koh, V Lewington, B Sharma, G Brown, ... European journal of nuclear medicine and molecular imaging 35, 1323-1329, 2008 | 170 | 2008 |
| Managing haematology and oncology patients during the COVID‐19 pandemic: interim consensus guidance R Weinkove, ZK McQuilten, J Adler, MR Agar, E Blyth, AC Cheng, ... Medical Journal of Australia 212 (10), 481-489, 2020 | 166 | 2020 |
| Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review J Stairmand, L Signal, D Sarfati, C Jackson, L Batten, M Holdaway, ... Annals of Oncology 26 (7), 1325-1332, 2015 | 121 | 2015 |
| Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up C Jackson, D Cunningham, J Oliveira Annals of Oncology 20, iv34-iv36, 2009 | 115 | 2009 |
| Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project) M Araghi, M Arnold, MJ Rutherford, MG Guren, CJ Cabasag, A Bardot, ... Gut 70 (1), 114-126, 2021 | 94 | 2021 |
| Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors J Desai, H Gan, C Barrow, M Jameson, V Atkinson, A Haydon, M Millward, ... Journal of Clinical Oncology 38 (19), 2140, 2020 | 84 | 2020 |
| Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience C Jackson, B Sirohi, D Cunningham, A Horwich, K Thomas, ... Annals of Oncology 21 (10), 2061-2068, 2010 | 83 | 2010 |
| Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy … P Gibbs, V Heinemann, NK Sharma, J Taieb, J Ricke, M Peeters, ... Clinical colorectal cancer 17 (4), e617-e629, 2018 | 67 | 2018 |
| Practical considerations for treating patients with cancer in the COVID-19 pandemic E Segelov, C Underhill, H Prenen, C Karapetis, C Jackson, L Nott, T Clay, ... JCO Oncology Practice 16 (8), 467-482, 2020 | 66 | 2020 |
| International trends in oesophageal cancer survival by histological subtype between 1995 and 2014 E Morgan, I Soerjomataram, AT Gavin, MJ Rutherford, P Gatenby, ... Gut 70 (2), 234-242, 2021 | 60 | 2021 |
| Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer … S McPhail, R Swann, SA Johnson, ME Barclay, H Abd Elkader, R Alvi, ... The Lancet Oncology 23 (5), 587-600, 2022 | 57 | 2022 |
| Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type … AG Hill, MP Findlay, ME Burge, C Jackson, PG Alfonso, L Samuel, ... Clinical Cancer Research 24 (10), 2276-2284, 2018 | 55 | 2018 |
| Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer B Lawrence, C Blenkiron, K Parker, P Tsai, S Fitzgerald, P Shields, ... NPJ genomic medicine 3 (1), 18, 2018 | 51 | 2018 |
| The New Zealand PIPER Project: colorectal cancer survival according to rurality, ethnicity and socioeconomic deprivation-results from a retrospective cohort study KJ Sharples, MJ Firth, VA Hinder, A Hill, M Jeffery, D Sarfati, C Brown, ... New Zealand Medical Association, 2018 | 50 | 2018 |
| The euthanasia debate: synthesising the evidence on New Zealander's attitudes J Young, R Egan, S Walker, A Graham-DeMello, C Jackson Kōtuitui: New Zealand Journal of Social Sciences Online 14 (1), 1-21, 2019 | 41 | 2019 |
| Dietary information for colorectal cancer survivors: an unmet need JM Pullar, A Chisholm, C Jackson The New Zealand Medical Journal (Online) 125 (1356), 27, 2012 | 38 | 2012 |
